Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Malignant Disease

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2010 Dec 16

PMID 21156410

Authors

Wenceslao Vasquez Jimenez

Luis Gonzalez Bayon

Jose Luis Garcia-Sabrido

Santiago Gonzalez Moreno

Affiliations

Soon will be listed here.

Abstract

Peritoneal Malignant Disease (PMD) is the presence of tumoral tissue on the peritoneal surface from primary tumors or tumors from other locations (e.g. digestive or gynecologic). It is a regional disease with poor prognosis when treated with repeated "debulking" and traditional systemic chemotherapy. Cytoreduction plus hyperthermic intraperitoneal chemotherapy (HIPEC) is a combined multimodal regional procedure aimed at reducing the macroscopic tumoral mass as much as possible and treating with chemotherapy the microscopic disease that is out of the scope of the surgeon. This combined treatment may change the natural history of PMD, it is translated into a higher overall survival and cancer-free survival and it offers the option of cure in selected cases. The high-complexity procedure is also associated with complications and mortality, but in similar rates as other major oncologic procedures.

References

Schmidt U, Dahlke M, Klempnauer J, Schlitt H, Piso P . Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005; 31(1):53-8. DOI: 10.1016/j.ejso.2004.09.011. View

Yan T, Deraco M, Baratti D, Kusamura S, Elias D, Glehen O . Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009; 27(36):6237-42. DOI: 10.1200/JCO.2009.23.9640. View

Hall J, Loggie B, Shen P, Beamer S, Case L, McQuellon R . Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg. 2004; 8(4):454-63. DOI: 10.1016/j.gassur.2003.12.014. View

Elias D, Gilly F, Boutitie F, Quenet F, Bereder J, Mansvelt B . Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2009; 28(1):63-8. DOI: 10.1200/JCO.2009.23.9285. View

van Grevenstein W, Hofland L, van Rossen M, Van Koetsveld P, Jeekel J, van Eijck C . Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers. Dig Dis Sci. 2007; 52(10):2775-83. DOI: 10.1007/s10620-007-9778-4. View

Gianola F, Sugarbaker P, Barofsky I, White D, Meyers C . Toxicity studies of adjuvant intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Am J Clin Oncol. 1986; 9(5):403-10. DOI: 10.1097/00000421-198610000-00009. View

Elias D, Gilly F, Quenet F, Bereder J, Sideris L, Mansvelt B . Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010; 36(5):456-62. DOI: 10.1016/j.ejso.2010.01.006. View

Mueller H, Hahn M, Simsa J . Cytoreductive surgery in the elderly patients--is it feasible?. Hepatogastroenterology. 2009; 55(88):2005-11. View

Atkins B, Shah A, Hutcheson K, Mangum J, Pappas T, Harpole Jr D . Reducing hospital morbidity and mortality following esophagectomy. Ann Thorac Surg. 2004; 78(4):1170-6. DOI: 10.1016/j.athoracsur.2004.02.034. View

10.

Cameron J, Riall T, Coleman J, Belcher K . One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006; 244(1):10-5. PMC: 1570590. DOI: 10.1097/01.sla.0000217673.04165.ea. View

11.

Dromain C, Leboulleux S, Auperin A, Goere D, Malka D, Lumbroso J . Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging. 2007; 33(1):87-93. DOI: 10.1007/s00261-007-9211-7. View

12.

Logan-Collins J, Lowy A, Robinson-Smith T, Kumar S, Sussman J, James L . VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol. 2007; 15(3):738-44. DOI: 10.1245/s10434-007-9699-7. View

13.

McQuellon R, Duckworth K . Health-related quality of life and cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Curr Probl Cancer. 2009; 33(3):203-18. DOI: 10.1016/j.currproblcancer.2009.06.008. View

14.

Sugarbaker P, Klecker R, Gianola F, Speyer J . Prolonged treatment schedules with intraperitoneal 5-fluorouracil diminish the local-regional nature of drug distribution. Am J Clin Oncol. 1986; 9(1):1-7. DOI: 10.1097/00000421-198602000-00001. View

15.

Chua T, Yan T, Saxena A, Morris D . Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg. 2009; 249(6):900-7. DOI: 10.1097/SLA.0b013e3181a45d86. View

16.

Ceelen W, Flessner M . Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2009; 7(2):108-15. DOI: 10.1038/nrclinonc.2009.217. View

17.

Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz F . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5):1248-59. DOI: 10.1200/JCO.2002.20.5.1248. View

18.

Koh J, Yan T, Glenn D, Morris D . Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2008; 16(2):327-33. DOI: 10.1245/s10434-008-0234-2. View

19.

Gonzalez-Moreno S . [Cytoreductive surgery and perioperative intraperitoneal chemotherapy for neoplasms with peritoneal dissemination: the time has come]. Cir Esp. 2006; 78(6):341-3. DOI: 10.1016/s0009-739x(05)70951-9. View

20.

Spratt J, Adcock R, Sherrill W, Travathen S . Hyperthermic peritoneal perfusion system in canines. Cancer Res. 1980; 40(2):253-5. View